BriaCell Pipeline Expansion to Ovarian Cancer (May 15): Bria-OVA+ Personalized Off-the-Shelf Cell-Based Immunotherapy, ATCC Cell-Line Licensing
BriaCell announced May 15 it has expanded its pipeline to include Bria-OVA+, a next-generation personalized off-the-shelf cell-based immunotherapy for ovarian cancer. The company licensed ovarian-cancer cell lines from American Type Culture Collection (ATCC) and has commenced development activities to support production of Bria-OVA+ for potential clinical use. The candidate is designed with additional immune-stimulating components to support enhanced anti-tumor activity, building on Phase 2 efficacy and tolerability data in metastatic breast cancer. The company is targeting ovarian cancer because an estimated 21,010 women in the US will be diagnosed in 2026 and approximately 12,450 will die from the disease, with ovarian cancer remaining the deadliest gynecologic cancer. The expansion adds to the BriaCell platform spanning Bria-IMT (metastatic breast), Bria-OTS+ (next-gen breast and prostate), Bria-PROS+ (prostate), and Bria-BRES+ (breast).